Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab for Prevention of Acute GVHD
NCT04112810Phase 2Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Mar 2020
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tildrakizumab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Medical College of Wisconsin. Primary endpoint: GVHD-free Relapse-Free Survival at 1 year. Started Mar 2020; status: completed.
02
Drugs
tildrakizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04112810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04112810.